HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robertson, J. Articles by Waldman, R. H. Search for Related Content PubMed Articles by Robertson, J. Articles by Waldman, R. H.

Evidence for the Presence of Components of the Alternative (Properdin) Pathway of Complement Activation in Respiratory Secretions¹

University of Florida, College of Medicine, Gainesville, Florida

Abstract

Activation of the alternative complement pathway by respiratory secretory IgA was demonstrated by incubating purified, aggregated preparations of serum and secretory IgA with neat human serum. No depletion of the early components (C1-4) was observed, but 63 and 70% of C3-9, respectively, were consumed. The C3-9-consuming capacity of heat-aggregated nasal secretions from an IgA-deficient volunteer was compared with heat-aggregated nasal secretions from a normal volunteer known to have secretory IgA. The normal nasal secretions consumed C3-9, whereas the IgA deficient secretions did not. Reconstitution of the nasal secretions from the IgA-deficient volunteer with purified secretory IgA produced alternative pathway activation.

Factor B of the alternative complement pathway was found to be present in 16 of 18 bronchoalveolar lavage samples (BALF) from normal volunteers. Simultaneous measurement of lavage and serum albumin and Factor B concentrations rendered it unlikely that Factor B was merely a transudative product from serum in half the samples but rather suggested that it may be a component of lower respiratory tract secretions. The presence of an intact alternative complement pathway in BALF was indicated by showing that cobra venom factor and endotoxin cleaved functionally pure human C3 when mixed with BALF, but had no effect on C3 in the absence of BALF.

Footnotes

¹ This work was supported by the National Cancer Institute, Contract NOL-CB-43857, National Institutes of Health, Grant AI-0034 and a grant from Florida Tuberculosis and Respiratory Disease Association.

This article has been cited by other articles:

				M. S. Bolger, D. S. Ross, H. Jiang, M. M. Frank, A. J. Ghio, D. A. Schwartz, and J. R. Wright Complement levels and activity in the normal and LPS-injured lung Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L748 - L759. [Abstract] [Full Text] [PDF]

				L. P. Nicod Lung defences: an overview Eur. Respir. Rev., December 1, 2005; 14(95): 45 - 50. [Abstract] [Full Text] [PDF]

				J. VanderMeer, Q. Sha, A. P. Lane, and R. P. Schleimer Innate Immunity of the Sinonasal Cavity: Expression of Messenger RNA for Complement Cascade Components and Toll-like Receptors Arch Otolaryngol Head Neck Surg, December 1, 2004; 130(12): 1374 - 1380. [Abstract] [Full Text] [PDF]

				W. T. Watford, A. J. Ghio, and J. R. Wright Complement-mediated host defense in the lung Am J Physiol Lung Cell Mol Physiol, November 1, 2000; 279(5): L790 - L798. [Abstract] [Full Text] [PDF]